FATE THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

10 Jan 2025 09:22:09 By NetDania Notify

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

03 Jan 2025 15:01:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

30 Dec 2024 08:52:19 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

26 Dec 2024 12:03:48 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

23 Dec 2024 09:24:21 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

19 Dec 2024 09:10:18 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

18 Dec 2024 08:46:00 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

13 Dec 2024 08:45:20 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

12 Dec 2024 09:17:16 By NetDania Notify

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

09 Dec 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

03 Dec 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Announces Leadership Transition

29 Nov 2024 12:05:00 By Nasdaq GlobeNewswire

Fate Therapeutics to Present at Upcoming December Investor Conferences

26 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence

18 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence

18 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

15 Nov 2024 08:46:29 By NetDania Notify

NetDania - New 12 months Low: FATE THERAPEUTICS INC. - COMMON STOCK

14 Nov 2024 08:54:48 By NetDania Notify

Fate Therapeutics Reports Third Quarter 2024 Financial Results and Business Updates

12 Nov 2024 15:01:00 By Nasdaq GlobeNewswire

Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting

09 Nov 2024 12:30:00 By Nasdaq GlobeNewswire

Fate Therapeutics Presents Pan-tumor Targeting Preclinical Data for FT836 MICA/B-targeted CAR T-cell Product Candidate at 2024 SITC Annual Meeting

08 Nov 2024 15:01:00 By Nasdaq GlobeNewswire